Results from a study published this week suggest a way to get the benefits of one class of diabetes drugs - thiazolidinediones, or TZDs, such Actos (pioglitazone, Takeda Pharmaceutical Co. Ltd.) and Avandia (rosiglitazone, GlaxoSmithKline plc) - without their side effects.